SOLB Solvay SA

Solvay successfully completes divestment of Ionquest® 290 and OPA business lines to Italmatch Chemicals

Solvay announced today that it has sold its Ionquest® 290 solvent extraction product line used in mining applications and its octylphosphonic acid (OPA) product lines to Italmatch Chemicals. With this sale Solvay satisfies all remaining obligations set forth by the European Union regarding the approval of its acquisition last year of Cytec Industries.

“We are confident that Italmatch’s expertise and commitment to its customers will ensure that the Ionquest® 290 and OPA businesses will continue to thrive and meet the market’s needs,” commented Michael J. Radossich, President, Solvay Technology Solutions global business unit. “Customer satisfaction and a seamless transition have always been our main focus and priority in this process.”

Solvay will continue to invest in and grow its remaining mining solutions portfolio. The sale is expected to close before the end of the quarter pending customary requirements and regulatory review.

FOLLOW US ON TWITTER @SOLVAYGROUP

An international chemical and advanced materials company, Solvay assists its customers in innovating, developing and delivering high-value, sustainable products and solutions which consume less energy and reduce CO2 emissions, optimize the use of resources and improve the quality of life. Solvay serves diversified global end markets, including automotive and aerospace, consumer goods and healthcare, energy and environment, electricity and electronics, building and construction as well as industrial applications. Solvay is headquartered in Brussels with about 30,900 employees spread across 53 countries. It generated pro forma net sales of € 12.4 bn in 2015, with 90% made from activities where it ranks among the world’s top 3 players. Solvay SA (SOLB.BE) is listed on Euronext in Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLB.BR).

EN
19/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solvay SA

Stijn Demeester
  • Stijn Demeester

Solvay/Expectations reset, yield remains attractive/BUY

We update our model and lower our Und. EBITDA estimates by c.12% to reflect Solvay's 2Q25 results and lowered guidance. We reduce our target price to €30 per share from €33.50 yet keep our BUY on the back of Solvay's attractive dividend yield.

Solvay SA: 1 director

A director at Solvay SA bought 1,083 shares at 27.740EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Wim Hoste
  • Wim Hoste

Solvay Feedback conference call

Below are the key highlights from the conference call. Solvay's 1Q25 uEBITDA dropped 15% to € 230m, in line with the recent profit warning. Solvay reiterated the (recently cut) FY25 underlying EBITDA guidance of € 880-930m (c. -12% at midpoint vs the previous € 1.0-1.05bn range), citing continued soft demand in a context of tariff and geopolitical uncertainty. Solvay had already stated to maintain FCF guidance of c. € 300m (on the back of more prudent capex spending) which however still means th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch